Vincristine Sulfate Injection 2 mg in 2 mL (3) Australia - English - Department of Health (Therapeutic Goods Administration)

vincristine sulfate injection 2 mg in 2 ml (3)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - acute leukaemia. in combination with other cytostatic drugs for hodgkin's disease, lymphosarcoma, reticulocyte sarcoma, rhabdomyosarcoma, neuroblastoma, and wilms' tumour.

Vincristine Sulfate Injection 1 mg in 1 mL (8) Australia - English - Department of Health (Therapeutic Goods Administration)

vincristine sulfate injection 1 mg in 1 ml (8)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - acute leukaemia. combined therapy in hodgkin?s disease, non-hodgkin lymphoma, including special forms of these condition, rhabdomyosarcoma, neuroblastoma, wilm?s tumour, osteosarcoma, ewing?s sarcoma, malignant melanoma, small-cell carcinoma of the lung, gynaecological tumours of childhood, carcinoma of the breast. idiopathic thrombocytopenic purpura (werlhof?s disease) in patients who have not responded to a splenectomy and short-term treatment with corticosteroids.

Vincristine Sulfate Injection 1 mg in 1 mL (7) Australia - English - Department of Health (Therapeutic Goods Administration)

vincristine sulfate injection 1 mg in 1 ml (7)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - ? acute leukemia. ? the treatment of hodgkin's disease, lymphoma ? malignant non-hodgkin's, (types, mixed-cell, histiocytic, undifferentiated, nodular lymphocytic and diffuse) ? rhabdomyosarcoma ? neuroblastoma ? wilms tumour ? osteogenic sarcoma ? mycosis fungoides, ? ewing's sarcoma ? breast cancer ? malignant melanoma ? small cell lung cancer ? gynecological tumors of childhood. true idiopathic thrombocytopenic purpura, refractory to splenectomy and to short-term treatment with adrenocortical steroids.

Vincristine Solution for Injection 1mg/ml Malta - English - Medicines Authority

vincristine solution for injection 1mg/ml

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - antineoplastic agents

VINCRISTINE SULPHATE INJECTION 5 MG/5ml Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

vincristine sulphate injection 5 mg/5ml solution for injection

hospira uk ltd - vincristine sulfate - solution for injection - 5 mg/5ml

Hospira Vincristine Sulphate 5 mg/5 mL Injection vial (preserved) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vincristine sulphate 5 mg/5 ml injection vial (preserved)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; mannitol; water for injections - vincristine sulphate injection is used in the treatment of cancers of the blood (eg. leukaemia or lymphomas), breast, head and neck or lung. it may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. it may be used in a blood disorder known as idiopathic thrombocytopenic purpura (itp) after other treatments have not been successful. vincristine sulphate injection may be given alone or in combination with other anti-cancer medicines.

Hospira Vincristine Injection, 2 mg/2 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vincristine injection, 2 mg/2 ml vial

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of: leukaemias, malignant lymphomas, multiple myeloma, breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma, soft tissue sacomas, paediatric solid tumours and idiopathic thrombocytopenic purpura.

Hospira Vincristine Sulphate 1 mg/1 mL Injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira vincristine sulphate 1 mg/1 ml injection vial

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: sulfuric acid; water for injections; mannitol; sodium hydroxide - vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of: 1. leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukemia and blastic crisis of chronic myelogenous leukaemia. 2. malignant lymphomas, including hodgkin's disease and non-hodgkin's lymphomas. 3. multiple myeloma. 4. solid tumors, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas. 5. paediatirc solid tumors, including ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, wilm's tumour, retinoblastoma and medulloblastoma. 6. idiopathic thrombocytytopenic pupura.

Vincristine (Wyeth) New Zealand - English - Medsafe (Medicines Safety Authority)

vincristine (wyeth)

wyeth (nz) ltd - vincristine sulfate - powder for injection - 1mg , 2mg ,5mg - active: vincristine sulfate

Vincristine Sulphate New Zealand - English - Medsafe (Medicines Safety Authority)

vincristine sulphate

baxter healthcare ltd - vincristine sulfate 1mg;  ;  ;   - injection with diluent - 1 mg - active: vincristine sulfate 1mg       excipient: lactose monohydrate benzyl alcohol sodium chloride water for injection